within Pharmacolibrary.Drugs.ATC.J;

model J05AJ04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.76,
    Cl             = 0.0021666666666666666,
    adminDuration  = 600,
    adminMass      = 0.03,
    adminCount     = 1,
    Vd             = 0.0123,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004333333333333333,
    Tlag           = 7.800000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Cabotegravir is a long-acting integrase strand transfer inhibitor (INSTI) used for the treatment and prevention of HIV-1 infection in adults and adolescents. It is approved for use in combination with rilpivirine for both treatment and pre-exposure prophylaxis (PrEP).</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic model in healthy adults, after a single 30 mg oral dose.</p><h4>References</h4><ol><li><p>Han, K, et al., &amp; Ford, SL (2024). Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP. <i>Antimicrobial agents and chemotherapy</i> 68(6) e0147523–None. DOI:<a href=&quot;https://doi.org/10.1128/aac.01475-23&quot;>10.1128/aac.01475-23</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38709006/&quot;>https://pubmed.ncbi.nlm.nih.gov/38709006</a></p></li><li><p>Thoueille, P, et al., &amp; Guidi, M (2024). Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV. <i>Clinical pharmacology and therapeutics</i> 115(6) 1450–1459. DOI:<a href=&quot;https://doi.org/10.1002/cpt.3240&quot;>10.1002/cpt.3240</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38519844/&quot;>https://pubmed.ncbi.nlm.nih.gov/38519844</a></p></li><li><p>Gaur, AH, et al., &amp; Bolton Moore, C (2024). Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study. <i>The lancet. HIV</i> 11(4) e211–e221. DOI:<a href=&quot;https://doi.org/10.1016/S2352-3018(23)00300-4&quot;>10.1016/S2352-3018(23)00300-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38538160/&quot;>https://pubmed.ncbi.nlm.nih.gov/38538160</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AJ04;
